Curium seeks FDA review of rival radioligand therapy to boost supply resilience against Novartis' Pluvicto

Curium is preparing to challenge Novartis' dominant prostate cancer radioligand therapy, Pluvicto, by entering discussions with the FDA about reviewing its own PSMA‑directed Lu‑177 candidate.

Novartis' Pluvicto has become a blockbuster since its first approval four years ago, generating $1.3 billion in sales in the first half of 2026, a rise of more than 50% compared with the same period a year earlier.

Curium believes a second Lu‑177 PSMA therapy could strengthen the radiopharma supply chain. The company points to its decades of manufacturing expertise as a way to provide additional options and improve resilience.

"People are looking for more options," said Michael Patterson, Curium's North America CEO, noting feedback from physicians and patients that supports the need for a competing product.